-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Videos|April 8, 2022

The Burden of ASCVD and Evidence-Based Guidelines

Ian Riddock, MD, discusses the burden of atherosclerotic cardiovascular disease (ASCVD) and multi-societal guideline recommendations for lipid management.

Episodes in this series

EP. 1 The Burden of ASCVD and Evidence-Based Guidelines

EP. 1 The Burden of ASCVD and Evidence-Based Guidelines

EP. 2 A Patient’s Post-MI Journey

EP. 2 A Patient’s Post-MI Journey

EP. 3 Improving the Care Continuum

EP. 3 Improving the Care Continuum

EP. 4 Residual Cardiovascular Risk

EP. 4 Residual Cardiovascular Risk

EP. 5 Who is an Ideal Patient for Early Intensive Lipid Lowering?

EP. 5 Who is an Ideal Patient for Early Intensive Lipid Lowering?

EP. 6 Finding the Optimal Statin Dose

EP. 6 Finding the Optimal Statin Dose

EP. 7 Therapy Beyond Statins in the Inpatient Setting

EP. 7 Therapy Beyond Statins in the Inpatient Setting

EP. 8 Using Adjunct Therapies in LDL Management

EP. 8 Using Adjunct Therapies in LDL Management

EP. 9 Ensuring Continuity of Care for the ASCVD Patient

EP. 9 Ensuring Continuity of Care for the ASCVD Patient

EP. 10 Unmet Needs in Lipid Management

EP. 10 Unmet Needs in Lipid Management

EP. 11 Defining “Optimal Care” for ASCVD Within Health Systems

EP. 11 Defining “Optimal Care” for ASCVD Within Health Systems

EP. 12 What Does a Multidisciplinary Team Look Like?

EP. 12 What Does a Multidisciplinary Team Look Like?

EP. 13 The Future of LDL Management for Patients With High-Risk ASCVD

EP. 13 The Future of LDL Management for Patients With High-Risk ASCVD

EP. 14 Enhancing Patient Care Through Guideline Adherence

EP. 14 Enhancing Patient Care Through Guideline Adherence

EP. 15 Improving Access to PCSK9 Inhibitors in the Inpatient Setting

EP. 15 Improving Access to PCSK9 Inhibitors in the Inpatient Setting

EP. 16 Appropriate ASCVD Treatment Outside of Closed Health Systems

EP. 16 Appropriate ASCVD Treatment Outside of Closed Health Systems

EP. 17 Utilizing Quality Metrics in ASCVD

EP. 17 Utilizing Quality Metrics in ASCVD

EP. 18 Improving Patient and Provider Engagement

EP. 18 Improving Patient and Provider Engagement

EP. 19 Treatment Disparities in the Management of ASCVD

EP. 19 Treatment Disparities in the Management of ASCVD

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Dr Julie Kanter | Image Credit: Inherited Blood Disorders

SCD Trials Should Shift Toward Broader End Points, Real-World Monitoring to Expand Eligiblity: Julie Kanter, MD

ByBrooke McCormick,Julie Kanter, MD

June 25th 2026

Kerry Rogers, MD

Managing Toxicity, Sequencing for Long-Term BTKIs: Kerry Rogers, MD

ByMaggie L. Shaw,Kerry Rogers, MD

June 25th 2026

Dr Claire Harrison | Image Credit: Guy's and St. Thomas' NHS Foundation Trust

Early SENTRY Data Suggest Benefit of Selinexor-Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis: Claire Harrison, MD

ByBrooke McCormick,Claire Harrison, MD

June 25th 2026

Julie Eastland, MBA, is the CEO of Zentalis, which is advancing a next-generation WEE1 inhibitor, azenosertib. | Image: Zentalis

More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor

June 25th 2026

Umberto Vitolo, MD, is the lead author of EPCORE DLBCL-3, presented at the European Hematology Association in Stockholm. | Image: Candiolo Cancer Institute

EHA Data for Epcoritamab Show Durable Responses in Older, Chemotherapy-Ineligible Patients With DLBCL

June 25th 2026

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance

ATTR-CM Incidence, Prevalence Rose Sharply in the US

Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups

Zanubrutinib Tops Rivals in Real-World CLL Survival Study